BridgeMD
Tests treatment safety and results for Atopic Dermatitis
Official title Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
ClinicalTrials.gov ID: NCT06947993
What this study is testing
What is GHZ339?
GHZ339 is an investigational medicine, being studied as a potential treatment for atopic dermatitis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 100
You may be able to join if
- Key of the master protocol:
- Able and willing to sign the informed consent (IC)
- Patients with a diagnosis of AD and onset of disease for at least 1 year
- Moderate to severe AD Key
You likely can't join if
- of the master protocol:
- Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
- Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
- Participant with any other active inflammatory skin disease
- Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g...
- Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma) Additional...
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Fort Smith, Arkansas, United States
- Fountain Valley, California, United States
- Los Angeles, California, United States
- Sacramento, California, United States
- Santa Ana, California, United States
- Santa Monica, California, United States
- Washington D.C., District of Columbia, United States
- Miami, Florida, United States
- Atlanta, Georgia, United States
- Macon, Georgia, United States
- Louisville, Kentucky, United States
- Brighton, Massachusetts, United States
- Troy, Michigan, United States
- Saint Joseph, Missouri, United States
- Brooklyn, New York, United States
- Arlington, Texas, United States
- Cypress, Texas, United States
- Dallas, Texas, United States
- Houston, Texas, United States
+ 70 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Fort Smith, Arkansas, United States; Fountain Valley, California, United States; Los Angeles, California, United States; Sacramento, California, United States; Santa Ana, California, United States and 84 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.